

# Developing research partnerships with academia

Feedback from breakout session 5D

EMA's Regulatory Science Strategy to 2025 – Human Stakeholder Workshop

Presented by Sabine Straus, PRAC and Violeta Stoyanova-Beninska, COMP on 19 November 2019



An agency of the European Union

#### Disclaimer



Comments to the underlying actions represent the views of stakeholders and not the European Medicines Agency.

The fact that these comments from stakeholders are displayed in the presentation does not mean we endorse them or commit to fulfil them in any way.

Develop network-led partnerships with academia to undertake fundamental research in strategic areas of regulatory science: **summary of written comments** 

#### Pre-consultation

#### Supported

- Identify, in consultation with academia and relevant stakeholders, fundamental research topics in strategic areas of regulatory science
- Proactively engage with DG Research & Innovation, DG-SANTE, IMI and MS funding agencies to propose and issue calls to establish research collaborations

#### Consultation feedback

#### **More ambition**

- Collaboration with academic research centres
- Role of industry in network-led partnerships
- Funders innovative funding models; explaining incentive models; opportunities for collaborative regulatory science initiatives
- Global consortia
- Regulatory science priorities incorporated into national and European translational calls
- Training/education pipeline of talent to support long-term future of regulatory science





Given 'the vision', in support of delivering for patients, create a Roadmap to develop Network-led partnerships with academia

- 1. Identify the gaps foreseen from RSS2025 how to address & take forward?
- 2. Key elements to be delivered: a Network-led partnership to address the following
  - Support for academics developing medicines
  - Regulator has a question where to take this?
    - `Wet lab' related
    - Clinical trials related
    - Epidemiology / RWD related
  - Translation & methods how to work together to define priorities, co-design modelling & simulation / CT / QoL methods, agree PROs, and so on?

#### **3. Associated education & training needs**

#### Enablers & barriers:

- Clear willingness of stakeholders to work with us & together, globally, transparently & for patient benefit
- Build on existing networks, platforms, infrastructures (EU-Innovation Network, JRC, ERN, EU lead factory, C4C)
- Use opportunities @DG R&I and others to voice research needs translated into funding
- Sustainable infrastructure & project based **funding** consider `wheel & spokes' funding model
  - Horizon EU incl. Innovative Health Initiative, Marie Curie
  - A budget line for EMA, EU-innovation network & National Competent Authorities
- Education & training from BSc to continuing professional development building on the work in STARS for the identification of training needs & existing offerings



#### The foreseen Network-led partnership with academia:

- benefits from a **clear vision** for EU public health and therefore
- has relevant stakeholders and funders at the table, acknowledging this may go beyond our usual Network and bringing in other decentralised Agencies, the DGs etc.
- is co-created with HMA / NCAs and includes a clear international dimension
- is developed **learning from existing models** e.g. from MEB, DKMA, AEMPS, FDA/CERSI
- identifies the questions relevant to patients & provides the signposting to address these (e.g. at national level, through the infrastructure itself, through a Horizon EU call, other).
- identifies the **training needs** of medicines developers, clinicians, regulators, others
- delivers on the above in a **continuous dialogue**, not as a one-way communication



## Any questions?

### Further information

RegulatoryScience2025@ema.europa.eu

Temporary visiting addressSpark building • Orlyplein 24 • 1043 DP Amsterdam • The NetherlandsFor deliveriesrefer to www.ema.europa.eu/how-to-find-usSend us a questionvia www.ema.europa.eu/contactTelephone +31 (0)88 781 6000



